CLEC-2 activates Syk through dimerization
In Cellular and Molecular Life Sciences, 2009
... Human α-thrombin was obtained from Enzyme Research Laboratories, recombinant human tissue factor came from Dade Behring, abciximab (reopro) from Centocor; tirofiban (aggrastat) from Merck Sharp & Dohme, and ... Upstream and downstream of mTOR
In BMC Cardiovascular Disorders, 2003
... tumor necrosis factor-α (TNF-α) was purchased from R & D, France); monoclonal mouse anti-TF antibody and tissue factor activity kit were purchased from American Diagnostica Inc (Socochim, Lausanne, Switzerland); ...
Acquired haemophilia: an overview for clinical practice.
Washington, D.C., United States. In Eur J Haematol, Dec 2015
Diagnosis involves an isolated prolongation of the activated partial thromboplastin time, without correction in mixing studies, low FVIII activity levels and evidence of a FVIII inhibitor.
Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.
Charlottesville, United States. In J Pediatr Pharmacol Ther, Nov 2015
The case reports and clinical studies currently available suggest that bivalirudin is as effective as heparin at reaching target activated clotting times or activated partial thromboplastin times, with equivalent or the lower rates of bleeding or thromboembolic complications.
Pancreatic cancer and thromboembolic disease, 150 years after Trousseau.
Lund, Sweden. In Hepatobiliary Surg Nutr, Oct 2015
The exact pathophysiological mechanisms are still partly understood, but it is known that pancreatic cancer induces a prothrombotic and hypercoagulable state and genetic events involved in neoplastic transformation (e.g., KRAS, c-MET, p53), procoagulant factors [e.g., tissue factor (TF), platelet factor 4 (PF4), plasminogen activator inhibitor type 1 (PAI-1)], mucin production (e.g., through activation of P- and L-selectin) and pro-inflammatory factors [e.g., cytokines, cyclooxygenase-2 (COX-2)] may be implicated.